NERLYNX: Market Expansion and Label Expansion
In a press release on July 31, Puma Biotechnology (PBYI) announced that Health Canada would review the company’s New Drug Submission for NERLYNX in the extended adjuvant setting for early-stage HER2-positive breast cancer after Herceptin-based adjuvant therapy.